Cellectis SA to Unveil Q3 2024 Financial Results
Company Announcements

Cellectis SA to Unveil Q3 2024 Financial Results

Cellectis SA (CLLS) has released an update.

Cellectis SA, a leader in gene-editing technology for cell and gene therapies, is set to release its third quarter 2024 financial results on November 4, following the market close. Investors can expect an update on business activities during a conference call on November 5. Cellectis continues to innovate in the field of CAR-T immunotherapies and gene editing solutions.

For further insights into CLLS stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated NewsdeskCellectis Presents New Gene-Editing Breakthroughs
TipRanks Auto-Generated NewsdeskCellectis’ Breakthrough in TNBC Therapy
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App